Abstract
Simultaneous inhibition of the two major constitutive protein quality control (PQC) pathways, that is, the ubiquitin-proteasome system (UPS) and the aggresome-autophagy system, has been suggested as a promising strategy to trigger cell death in cancer cells. However, we observed that one third of rhabdomyosarcoma (RMS) cells survives parallel inhibition of the UPS by Bortezomib and the aggresome-autophagy pathway by the cytoplasmic histone deacetylase 6 inhibitor ST80, and is able to regrow upon drug removal, thus pointing to the induction of compensatory pathways. Here, we identify Bcl-2-associated athanogene 3 (BAG3) as a critical mediator of inducible resistance in surviving cells after concomitant blockage of constitutive PQC pathways by mitigating ST80/Bortezomib-triggered proteotoxicity via selective autophagy. ST80/Bortezomib cotreatment upregulates BAG3 mRNA and protein levels in surviving cells in addition to triggering the accumulation of insoluble protein aggregates. Intriguingly, knockdown of BAG3 by RNA interference severely impairs clearance of protein aggregates, significantly increases cell death and reduces long-term survival and clonogenic growth during recovery after ST80/Bortezomib cotreatment. Similarly, inhibition of autophagy by inducible autophagy-related protein 7 knockdown prevents removal of protein aggregates and cell regrowth during recovery after ST80/Bortezomib cotreatment. Also, the inhibition of lysosomal degradation using the V-ATPase pump inhibitor Bafilomycin A1 enhances accumulation of protein aggregates, and completely abolishes regrowth after Bortezomib/ST80-induced proteotoxic stress. By identifying BAG3 as a key mediator of inducible resistance by mitigating proteotoxicity via selective autophagy after inhibition of constitutive PQC systems, our study provides new insights into the regulation of PQC pathways in cancer cells and identifies new targets for therapeutic intervention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kubota H . Quality control against misfolded proteins in the cytosol: a network for cell survival. J Biochem 2009; 146: 609–616.
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP . The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727–738.
Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. Embo J 2010; 29: 969–980.
Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y . Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol 2009; 10: 458–467.
Behrends C, Fulda S . Receptor proteins in selective autophagy. Int J Cell Biol 2012; 2012: 673290.
Yao TP . The role of ubiquitin in autophagy-dependent protein aggregate processing. Genes & cancer 2010; 1: 779–786.
Lamark T, Johansen T . Aggrephagy: selective disposal of protein aggregates by macroautophagy. Int J Cell Biol 2012; 2012: 736905.
Gamerdinger M, Hajieva P, Kaya AM, Wolfrum U, Hartl FU, Behl C . Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3. Embo J 2009; 28: 889–901.
Carra S, Seguin SJ, Lambert H, Landry J . HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. J Biol Chem 2008; 283: 1437–1444.
Frankland-Searby S, Bhaumik SR . The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta 2012; 1825: 64–76.
Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC et al. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008; 14: 7340–7347.
Carew JS, Medina EC, Esquivel 2nd JA, Mahalingam D, Swords R, Kelly K et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 2010; 14: 2448–2459.
Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 2009; 69: 4415–4423.
Bersani F, Taulli R, Accornero P, Morotti A, Miretti S, Crepaldi T et al. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer 2008; 44: 876–884.
Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schafer S et al. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res 2008; 6: 1250–1258.
Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, Sakamoto KM . Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 2008; 68: 2557–2560.
Ding WX, Yin XM . Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy 2008; 4: 141–150.
Tsukahara F, Maru Y . Bag1 directly routes immature BCR-ABL for proteasomal degradation. Blood 2010; 116: 3582–3592.
Basit F, Humphreys R, Fulda S . RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis. J Biol Chem 2012; 287: 38767–38777.
Behl C . BAG3 and friends: co-chaperones in selective autophagy during aging and disease. Autophagy 2011; 7: 795–798.
Wu WK, Sakamoto KM, Milani M, Aldana-Masankgay G, Fan D, Wu K et al. Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy. Drug Resist Updat 2010; 13: 87–92.
Gamerdinger M, Carra S, Behl C . Emerging roles of molecular chaperones and co-chaperones in selective autophagy: focus on BAG proteins. J Mol Med 2011; 89: 1175–1182.
Gamerdinger M, Kaya AM, Wolfrum U, Clement AM, Behl C . BAG3 mediates chaperone-based aggresome-targeting and selective autophagy of misfolded proteins. EMBO Rep 2011; 12: 149–156.
Nivon M, Abou-Samra M, Richet E, Guyot B, Arrigo AP, Kretz-Remy C . NF-kappaB regulates protein quality control after heat stress through modulation of the BAG3-HspB8 complex. J Cell Sci 2012; 125: 1141–1151.
Festa M, Del Valle L, Khalili K, Franco R, Scognamiglio G, Graziano V et al. BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol 2011; 178: 2504–2512.
Liao Q, Ozawa F, Friess H, Zimmermann A, Takayama S, Reed JC et al. The anti-apoptotic protein BAG-3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines. FEBS Lett 2001; 503: 151–157.
Chiappetta G, Ammirante M, Basile A, Rosati A, Festa M, Monaco M et al. The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Clin Endocrinol Metab 2007; 92: 1159–1163.
Romano MF, Festa M, Petrella A, Rosati A, Pascale M, Bisogni R et al. BAG3 protein regulates cell survival in childhood acute lymphoblastic leukemia cells. Cancer Biol Ther 2003; 2: 508–510.
Ammirante M, Rosati A, Arra C, Basile A, Falco A, Festa M et al. IKK{gamma} protein is a target of BAG3 regulatory activity in human tumor growth. Proc Natl Acad Sci USA 2010; 107: 7497–7502.
Aveic S, Pigazzi M, Basso G . BAG1: the guardian of anti-apoptotic proteins in acute myeloid leukemia. PLoS One 2011; 6: e26097.
Zhang Y, Wang JH, Lu Q, Wang YJ . Bag3 promotes resistance to apoptosis through Bcl-2 family members in non-small cell lung cancer. Oncol Rep 2012; 27: 109–113.
Wang HQ, Liu HM, Zhang HY, Guan Y, Du ZX . Transcriptional upregulation of BAG3 upon proteasome inhibition. Biochem Biophys Res Commun 2008; 365: 381–385.
Du ZX, Zhang HY, Meng X, Gao YY, Zou RL, Liu BQ et al. Proteasome inhibitor MG132 induces BAG3 expression through activation of heat shock factor 1. J Cell Physiol 2009; 218: 631–637.
Seidel K, Vinet J, Dunnen WF, Brunt ER, Meister M, Boncoraglio A et al. The HSPB8-BAG3 chaperone complex is upregulated in astrocytes in the human brain affected by protein aggregation diseases. Neuropathol Appl Neurobiol 2012; 38: 39–53.
Humphreys RC, Halpern W . Trail receptors: targets for cancer therapy. Adv Exp Med Biol 2008; 615: 127–158.
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D . Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871–875.
Gonzalez P, Mader I, Tchoghandjian A, Enzenmuller S, Cristofanon S, Basit F et al. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ 2012; 19: 1337–1346.
Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM . The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823–3829.
Garcia-Mata R, Bebok Z, Sorscher EJ, Sztul ES . Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol 1999; 146: 1239–1254.
Wanker EE, Scherzinger E, Heiser V, Sittler A, Eickhoff H, Lehrach H . Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Methods Enzymol 1999; 309: 375–386.
Acknowledgements
We thank C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Wilhelm-Sander Stiftung, the Deutsche Krebshilfe and the Bundesministerium für Bildung und Forschung (01GM1104C) (to S F). Work on HDAC inhibitors in the Jung group is supported by the Deutsche Forschungsgemeinschaft (JU 295/9-1 within SPP1463, JU 295/10-2 within CRU 201).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Rapino, F., Jung, M. & Fulda, S. BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways. Oncogene 33, 1713–1724 (2014). https://doi.org/10.1038/onc.2013.110
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.110
Keywords
This article is cited by
-
BAG family proteins contributes to autophagy-mediated multidrug resistance of tumor
Clinical and Translational Oncology (2022)
-
Knockdown of Bcl-2-Associated Athanogene-3 Can Enhance the Efficacy of BGJ398 via Suppressing Migration and Inducing Apoptosis in Gastric Cancer
Digestive Diseases and Sciences (2021)
-
Differential regulation of autophagy by STAU1 in alveolar rhabdomyosarcoma and non‐transformed skeletal muscle cells
Cellular Oncology (2021)
-
Lamin B is a target for selective nuclear PQC by BAG3: implication for nuclear envelopathies
Cell Death & Disease (2019)
-
BAG3 promotes autophagy and glutaminolysis via stabilizing glutaminase
Cell Death & Disease (2019)